SCHEMBL4592972

SCHEMBL4592972

C=CCOc1ccc(C[S+]([O-])CCn2ccnn2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
POLB P06746 2/20 0.36
USP2 O75604 1/20 0.36
MAPT P10636 1/20 0.36
CACNA1B Q00975 1/20 0.36
APBA1 Q02410 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA7 P43166 1/20 0.35
CA9 Q16790 1/20 0.35
ATP4A P20648 1/20 0.34
ATP4B P51164 1/20 0.34
HPGD P15428 1/20 0.34
CYP19A1 P11511 4/20 0.33
DCTPP1 Q9H773 1/20 0.32
ERBB2 P04626 1/20 0.32
MINK1 Q8N4C8 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4606288 0.83 MAOA (0.33) ALDH1A1HPGD
SCHEMBL6027103 0.81 CYP19A1 (0.47) ATP4AATP4BHPGDCYP19A1
SCHEMBL4600205 0.77 CYP19A1 (0.41) CYP19A1
SCHEMBL4592008 0.77 ALDH1A1 (0.38) ALDH1A1POLBUSP2MAPTCACNA1B
SCHEMBL4599530 0.76 ALDH1A1 (0.38) ALDH1A1POLBUSP2MAPTCACNA1B
SCHEMBL5044837 0.74 ALDH1A1 (0.41) ALDH1A1POLBUSP2MAPTCACNA1B
SCHEMBL4518195 0.74 ALDH1A1 (0.38) ALDH1A1POLBUSP2MAPTCACNA1B
SCHEMBL27658568 0.72 CA12 (0.46) ALDH1A1POLBUSP2MAPTCACNA1B
SCHEMBL4607023 0.69 ESR1 (0.39) CYP19A1
SCHEMBL27678886 0.69 CA12 (0.34) ALDH1A1POLBUSP2MAPTCACNA1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7429605-B2 Phenylpyridine derivatives HOFFMANN-LA ROCHE INC. (US) 2008-09-30 US disclosed
US-7405231-B2 Anticancer agents; inhibitors of the HER-signaling pathway with decreased toxicity, better solubility and improved pharmacokinetic profile; e.g. 1-[4-(4-(2-[(E)-2-(4-Methanesulfinyl-phenyl)-vinyl]-oxazol-4-ylmethoxy)-phenyl)-butyl]-1H-[1,2,3]triazole HOFFMANN-LA ROCHE INC. (US) 2008-07-29 US disclosed
EP-1761525-B1 THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2008-07-23 EP disclosed
CN-101213186-A Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2008-07-02 CN disclosed
EP-1912969-A1 PHENYLPYRIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F.HOFFMANN-LA ROCHE AG (CH) 2008-04-23 EP disclosed
US-7342030-B2 Indole derivatives HOFFMANN-LA ROCHE INC. (US) 2008-03-11 US disclosed
CN-101010319-A Indole derivatives, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-08-01 CN disclosed
US-7235574-B2 Pentafluorosulfanyl compounds HOFFMANN-LA ROCHE INC. (US) 2007-06-26 US disclosed
EP-1797086-A1 INDOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. Hoffmann-Roche AG (CH) 2007-06-20 EP disclosed
CN-1930153-A Pentafluorosulfanyl compounds, their preparation and use as pharmaceutical agents HOFFMANN LA ROCHE (CH) 2007-03-14 CN disclosed
EP-1725551-A1 OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS F.HOFFMANN-LA ROCHE AG (CH) 2006-11-29 EP disclosed
WO-2006032509-A1 INDOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2006-03-30 WO disclosed
US-20060063812-A1 Indole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2006-03-23 US disclosed
US-7005526-B2 Thioether derivatives HOFFMANN-LA ROCHE INC. (US) 2006-02-28 US disclosed
WO-2005116019-A1 THIOETHER DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-12-08 WO disclosed
US-20050267179-A1 NOVEL THIOETHER DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-12-01 US disclosed
WO-2005095388-A1 PENTAFLUOROSULFANYL COMPOUNDS, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-13 WO disclosed
WO-2005095393-A1 OXIDIZED THIOETHER DERIVATIVES OF STYRYL-AZOLES AND THEIR USE AS HER TYROSINE KINASES INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2005-10-13 WO disclosed
US-20050203064-A1 Novel oxidized thioether derivatives F. HOFFMANN-LA ROCHE AG (CH) 2005-09-15 US disclosed
US-20050197370-A1 Novel pentafluorosulfanyl compounds HOFFMANN-LA ROCHE INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197370-A1 Novel pentafluorosulfanyl compounds SF3B5, SF3B1, SF3B3 ALDH1A1 171/4885POLB 2749/4885USP2 3389/4885
US-20050267179-A1 NOVEL THIOETHER DERIVATIVES TPMT, TST, SULT1E1 ALDH1A1 129/4885POLB 4538/4885USP2 4201/4885
US-20050203064-A1 Novel oxidized thioether derivatives SULT1E1, CYP4F3, GPX4 ALDH1A1 89/4885POLB 3098/4885USP2 3632/4885
US-20060063812-A1 Indole derivatives IDO1, IDO2, TPH1 ALDH1A1 123/4885POLB 3684/4885USP2 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.